Stephen Mason Sells 35,000 Shares of Cardinal Health (NYSE:CAH) Stock

Cardinal Health, Inc. (NYSE:CAH) CEO Stephen Mason sold 35,000 shares of the stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $236.40, for a total value of $8,274,000.00. Following the completion of the sale, the chief executive officer directly owned 18,061 shares in the company, valued at approximately $4,269,620.40. This represents a 65.96% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Cardinal Health Price Performance

CAH opened at $229.48 on Friday. The stock has a 50-day moving average price of $232.02 and a 200-day moving average price of $217.86. The firm has a market cap of $53.37 billion, a PE ratio of 31.74, a P/E/G ratio of 1.22 and a beta of 0.49. Cardinal Health, Inc. has a 1 year low of $145.87 and a 1 year high of $258.30.

Cardinal Health (NYSE:CAH) last announced its quarterly earnings data on Tuesday, August 11th. The company reported $2.91 EPS for the quarter, beating the consensus estimate of $2.42 by $0.49. The company had revenue of $63.67 billion for the quarter, compared to the consensus estimate of $65.15 billion. Cardinal Health had a net margin of 0.67% and a negative return on equity of 98.53%. Cardinal Health’s revenue for the quarter was up 5.8% on a year-over-year basis. During the same period in the prior year, the firm posted $2.08 EPS. Cardinal Health has set its FY 2027 guidance at 12.400-12.600 EPS. As a group, sell-side analysts anticipate that Cardinal Health, Inc. will post 12.54 EPS for the current year.

Cardinal Health Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, October 15th. Stockholders of record on Thursday, October 1st will be issued a dividend of $0.5158 per share. The ex-dividend date is Thursday, October 1st. This represents a $2.06 dividend on an annualized basis and a dividend yield of 0.9%. Cardinal Health’s dividend payout ratio is presently 28.49%.

Analyst Ratings Changes

Several equities analysts recently issued reports on CAH shares. Robert W. Baird upped their price objective on Cardinal Health from $251.00 to $274.00 and gave the company an “outperform” rating in a research report on Wednesday, August 12th. Mizuho lifted their target price on Cardinal Health from $240.00 to $250.00 and gave the stock an “outperform” rating in a report on Wednesday, August 12th. Citigroup upped their price target on Cardinal Health from $265.00 to $280.00 and gave the company a “buy” rating in a report on Wednesday, August 12th. Morgan Stanley increased their price objective on Cardinal Health from $255.00 to $265.00 and gave the company an “overweight” rating in a research report on Wednesday, August 12th. Finally, UBS Group upped their target price on shares of Cardinal Health from $274.00 to $280.00 and gave the company a “buy” rating in a research note on Wednesday, August 12th. Sixteen equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $266.56.

Cardinal Health News Summary

Here are the key news stories impacting Cardinal Health this week:

• Positive Sentiment: Royal Bank of Canada initiated coverage with an “outperform” rating and a $276 price target, implying meaningful upside from recent trading levels. RBC cited Cardinal Health’s higher-margin services as a potential earnings-growth driver. RBC initiates coverage of Cardinal Health
• Positive Sentiment: Wall Street remains broadly constructive, with 16 analysts rating CAH a Buy and three assigning a Hold rating. The consensus rating is “Moderate Buy,” with an average price target of approximately $266.56. Zacks also identified Cardinal Health as a potentially attractive long-term value stock. Zacks value-stock analysis
• Positive Sentiment: Cardinal Health’s latest quarter delivered adjusted earnings per share of $2.91, well above the $2.42 consensus estimate, while revenue increased 5.8% year over year. Fiscal 2027 EPS guidance of $12.40–$12.60 supports the longer-term earnings case.
• Neutral Sentiment: The company declared a quarterly dividend of $0.5158 per share, equivalent to $2.06 annually and a yield of about 0.9%. The payout offers modest income support but is unlikely to be a major near-term catalyst.
• Negative Sentiment: Several executives sold sizable holdings around $235–$237 per share. CEO Jason Hollar sold 124,529 shares worth about $29.4 million, while other executive and insider sales—including those by Deborah Weitzman, Stephen Mason, Michelle Greene, Jessica Mayer and Mary Scherer—totaled roughly $20 million more. The concentrated selling and substantial reductions in insider ownership may encourage profit-taking concerns after CAH’s strong advance. Cardinal Health insider sales
• Negative Sentiment: Investors may also question the durability of the latest earnings beat because part of the improvement reportedly reflected a one-time tariff refund, potentially limiting the stock’s upside if recurring earnings growth does not match expectations. Cardinal Health earnings analysis

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the business. NEOS Investment Management LLC boosted its stake in shares of Cardinal Health by 10.4% during the 2nd quarter. NEOS Investment Management LLC now owns 37,684 shares of the company’s stock worth $8,933,000 after acquiring an additional 3,549 shares during the last quarter. Power Wealth Management LLC purchased a new stake in shares of Cardinal Health in the 2nd quarter worth $261,000. AXQ Capital LP raised its holdings in Cardinal Health by 30.8% in the 2nd quarter. AXQ Capital LP now owns 9,817 shares of the company’s stock worth $2,332,000 after purchasing an additional 2,312 shares during the period. Continuum Advisory LLC bought a new position in Cardinal Health in the 2nd quarter worth $171,000. Finally, Nykredit A S purchased a new position in Cardinal Health during the second quarter valued at $17,167,000. 87.17% of the stock is currently owned by institutional investors.

About Cardinal Health

Cardinal Health is a multinational healthcare services and products company headquartered in Dublin, Ohio. Tracing its roots to the early 1970s, the company has grown into a major provider of supply chain and distribution services for the healthcare sector. Cardinal Health operates across a range of service lines that support hospitals, health systems, pharmacies, physician offices and clinical laboratories.

The company’s core activities include the wholesale distribution of branded and generic pharmaceuticals, the supply and distribution of medical-surgical products, and the provision of logistics and inventory management solutions.